Skip to main content

What the FDA labels say about taking them together

Erlotinib and vonoprazan

Vonoprazan's FDA label of July 16, 2026 names erlotinib in its drug interactions section; the erlotinib label PlainMeds reads does not name vonoprazan. The vonoprazan label: “Other Drugs Clinical Effect Vonoprazan reduces intragastric acidity, which may decrease the absorption of drugs reducing their effectiveness.”

Check it at the source: the erlotinib FDA label on DailyMed (effective June 10, 2024, Alembic Pharmaceuticals Limited); the vonoprazan FDA label on DailyMed (effective July 16, 2026, Phathom Pharmaceuticals Inc.).

What does the erlotinib label say about vonoprazan?

Erlotinib's label (effective June 10, 2024) does not name vonoprazan in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (ERLOTINIB HYDROCHLORIDE), Alembic Pharmaceuticals Limited, effective June 10, 2024 (SPL set ab6f3cb3-34a8-4492-a5d7-fb6b055a2d6b), via openFDA; the full label on DailyMed

What does the vonoprazan label say about erlotinib?

Vonoprazan label, drug interactions

Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2) ], which may decrease the absorption of drugs reducing their effectiveness.

Source: FDA drug label (VOQUEZNA), Phathom Pharmaceuticals Inc., effective July 16, 2026 (SPL set 0cc52ac5-77ec-4d66-a770-762a1a960914), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

10Erlotinib generic labelers
0Vonoprazan generic labelers
ErlotinibVonoprazan
Labeled forLung cancerAcid reflux and ulcers
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$22.41 per tablet 20 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?